These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 20706150)

  • 81. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
    Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study.
    Kiljander TO; Junghard O; Beckman O; Lind T
    Am J Respir Crit Care Med; 2010 May; 181(10):1042-8. PubMed ID: 20110554
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Water load test before and after PPI therapy in patients with gastro-oesophageal reflux disease.
    Battaglia E; Grassini M; Navino M; Niola P; Verna C; Mazzocchi A; Clerici C; Morelli A; Bassotti G
    Dig Liver Dis; 2007 Dec; 39(12):1052-6. PubMed ID: 17913607
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Changes of intercellular spaces of esophageal epithelium in patients with gastroesophageal reflux disease before and after esomeprazole treatment].
    Tao J; Xiao YL; Chen MH; Peng S; Lin JK; Xiong LS; Hu PJ
    Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):392-5. PubMed ID: 17456380
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
    Lim H; Park JK; Chung H; Lee SH; Park JM; Park JH; Kim GH; Shin SK; Hong SJ; Lee KJ; Park MI; Jung HK; Kim HS; Sung JK; Jeon SW; Choi SC; Moon JS; Kim N; Park JJ; Hong SH; Kim NY; Jung HY
    BMC Gastroenterol; 2023 Dec; 23(1):447. PubMed ID: 38110901
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease.
    Labenz J; Nocon M; Lind T; Leodolter A; Jaspersen D; Meyer-Sabellek W; Stolte M; Vieth M; Willich SN; Malfertheiner P
    Am J Gastroenterol; 2006 Nov; 101(11):2457-62. PubMed ID: 17029609
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease.
    Bardhan KD; Achim A; Riddermann T; Pfaffenberger B
    Aliment Pharmacol Ther; 2007 Jun; 25(12):1461-9. PubMed ID: 17539986
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effect of pantoprazole in older patients with erosive esophagitis.
    DeVault KR; Morgenstern DM; Lynn RB; Metz DC
    Dis Esophagus; 2007; 20(5):411-5. PubMed ID: 17760655
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
    Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
    Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].
    Maev IV; Viuchnova ES; Balashova NN; Shchekina MI
    Eksp Klin Gastroenterol; 2003; (3):26-31, 116. PubMed ID: 14556543
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis.
    Sheu BS; Cheng HC; Chang WL; Chen WY; Kao AW
    Am J Gastroenterol; 2007 Nov; 102(11):2387-94. PubMed ID: 17850409
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Empirical treatment for the management of patients presenting with uninvestigated reflux symptoms: a prospective study in an Asian primary care population.
    Ho KY; Gwee KA; Khor CJ; Selamat DS; Wai CT; Yeoh KG
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1313-20. PubMed ID: 15932361
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
    DelGaudio JM; Waring JP
    Laryngoscope; 2003 Apr; 113(4):598-601. PubMed ID: 12671413
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P; Vakil N; Monyak JT; Silberg DG
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.
    Zhuang Q; Liao A; He Q; Liu C; Zheng C; Li X; Liu Y; Wang B; Liu S; Zhang Y; Lin R; Chen H; Deng M; Tang Y; He C; Dai W; Tang H; Gong L; Li L; Xu B; Yang C; Zhou B; Su D; Guo Q; Li B; Zhou Y; Wang X; Fei S; Wu H; Wei S; Peng Z; Wang J; Li Y; Wang H; Deng T; Ding S; Li F; Chen M; Xiao Y
    J Gastroenterol Hepatol; 2024 Apr; 39(4):658-666. PubMed ID: 38251791
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
    van Zanten SV; Armstrong D; Chiba N; Flook N; White RJ; Chakraborty B; Gasco A
    Am J Gastroenterol; 2006 Sep; 101(9):2096-106. PubMed ID: 16817845
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1165-71. PubMed ID: 19298581
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
    Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
    Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.